# NovaSignal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novasignal

- Industry: Medical Devices & Equipment
- Headquarters: Los Angeles, US
- Website: www.neuralanalytics.com
- Total disclosed funding: $66M
- Latest round: Series C (Sep 28, 2021)
- Investors on record: 6

## About

NovaSignal Corp. is focused on innovative technologies for diagnosing and treating neurological disorders, utilizing advanced ultrasound methods to enhance brain health assessments.Founded in 2013, NovaSignal Corp. develops technologies for neurological diagnostics. Headquartered in Los Angeles, US, the company has completed 10 deals, with its latest being a Series C funding round that raised USD 15.000 mn on September 28, 2021, led by investors Alpha Edison and Reimagined Ventures. The company's current valuation stands at USD 175.253 mn. The founders, Dan Hanchey and Robert Hamilton, have previously created other ventures in the health tech space, contributing to the company's innovative approach.Neural Analytics specializes in advanced technologies for the diagnosis and treatment of neurological disorders, primarily focusing on brain health. Their core product offerings include a proprietary platform that utilizes cutting-edge ultrasound technology to assess cerebral blood flow and other critical biomarkers. These products are designed to assist healthcare professionals in making informed decisions regarding various neurological conditions, such as traumatic brain injury and stroke. By providing accurate, real-time data, the company aims to improve patient outcomes and streamline clinical workflows. Neural Analytics serves a diverse client base that includes hospitals, rehabilitation centers, and research institutions across North America and Europe, where their products are actively utilized to enhance patient care in emergency and surgical settings.Neural Analytics generates revenue through a business-to-business model, establishing partnerships with healthcare facilities that implement their innovative diagnostic solutions. Transactions are structured through direct sales of their flagship products, which may include various subscription services for software updates and support. The company’s revenue stream is bolstered by contractual agreements with hospitals and clinics, ensuring ongoing access to necessary tools for monitoring and managing neurological health. Pricing plans are aligned with the needs of medical institutions and may include tiered offerings, catering to different levels of service and support for their core ultrasound diagnostic products. This approach not only secures steady revenue but also reinforces customer loyalty as healthcare providers rely on continuous advancements in technology and service.NovaSignal Corp. will utilize the USD 15.000 mn raised in Series C funding in September 2021 to support its commercial expansion, the delivery of product innovation, and new clinical trials aimed at increasing indications within and beyond stroke. They plan to develop and launch upcoming products designed to enhance diagnostic capabilities in neurological health. The company is also targeting expansion into new geographic markets, focusing on both North America and Europe in the coming years to broaden their service reach.

## Funding rounds

- Series C, Sep 28, 2021, $15M — Alpha Edison, Qstar Capital
- Series C, Apr 22, 2019, $24M — Alpha Edison
- Series B, Dec 12, 2017, $15M — Alpha Edison, Qstar Capital
- Series A, Dec 21, 2015, $10M — JSR Corporation, Ultrapower Fund
- Seed, Apr 11, 2014, $1.4M — Pasadena Angels, Tech Coast Angels

## Investors

- Pasadena Angels (https://capitalatlas.ai/funds/pasadena-angels) — Seed
- Tech Coast Angels — Seed
- JSR Corporation — Series A
- Ultrapower Fund — Series A
- Alpha Edison (https://capitalatlas.ai/funds/alpha-edison) — Series B, Series C
- Qstar Capital (https://capitalatlas.ai/funds/qstar-capital) — Series B, Series C